AstraZeneca said its cancer drug Imfinzi, combined with Amgen’s Imdelltra, significantly improved overall survival for patients with extensive-stage small-cell lung cancer. The companies reported the results from the late-stage DeLLphi-305 trial on Tuesday. The study tested the combination as a maintenance treatment after patients completed initial therapy with Imfinzi and platinum chemotherapy. The findings could… Continue reading Imfinzi Imdelltra Combo Shows Lung Cancer Survival Benefit
Imfinzi Imdelltra Combo Shows Lung Cancer Survival Benefit